glp-1 receptor agonist pancreatitis risk meta-analysis Frontiers Results of cardiovascular outcomes trials
Description
Safety profile of semaglutide
Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis Luis M
Clinical Trials.gov
Whether you are exploring semaglutide , tirzepatide , or newer options like retatrutide , the approach is the same
Slow dose escalation mitigates these effects substantially, and discontinuation due to gastrointestinal intolerance ranges from 3% to 16% across agents, being highest for GLP-1/glucagon dual agonists (e.g., survodutide)
no role in collection, management or interpretation of the data
